Abstract

A device for electrochemical measurement gas permeability includes a vessel (1), a working electrode (2) and a pressure chamber (3), where the vessel (1) contains an electrolyte (11), an auxiliary electrode (13) and a bubbler (14) with an inert gas. The working electrode (2) is provided with a catalyst support (21) in the form of a grid on which there is the catalyst layer. The working electrode (2) is further provided with a measured sample, which is located under the catalyst support (21). The pressure chamber (3) is provided with a gas inlet tube (31), where the working electrode (2) is located between the vessel (1) and the pressure chamber (3). The vessel (1), the working electrode (2) and the pressure chamber adhere gas-tight to each other.

IPC Classes  ?

• G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials

Abstract

The present disclosure provides a method for the detection and/or identification of reducing monosaccharides or oligosaccharides by mass spectrometry in a sample, wherein the reducing saccharide(s) in the sample is (are) reacted with a ligand of general formula I (I), wherein L is selected from the group comprising, wherein n is from 1 to 3,,,, wherein m is 1 or 2, and, wherein in the general formula I the methoxyphenol group is bound to the carbon atom of the linker L, where R1, R2 and R4 are independently selected from the group comprising hydrogen atom and, wherein R3 is selected from the group comprising hydrogen atom and methyl, to form a conjugate by reaction of the aldehyde group(s) of the reducing monosaccharide(s) and oligosaccharide(s) present in the sample with the NH2 group of the ligand, and the conjugate is subsequently subjected to ionization and mass spectrometry measurement. This method can be used also for detection or identification of microbial polysaccharides by mass spectrometry, wherein prior to the reaction with the ligand, the polysaccharides are cleaved enzymatically or by acid hydrolysis to reducing monosaccharides and/or oligosaccharides.

IPC Classes  ?

• G01N 33/66 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood sugars, e.g. galactose
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C07C 15/16 - Polycyclic non-condensed hydrocarbons containing at least two phenyl groups linked by one single acyclic carbon atom

Abstract

Method for precision application of catalytic inks, where continuous dispenser (2) and grooved film applicator (3) are placed above plane of deposition substrate (5), grooved film applicator (3) is pressed against deposition substrate (5), continuous dispenser (2) and deposition substrate (5) move relative to each other in such a way that deposition substrate (5) runs under continuous dispenser (2), catalytic ink (1) flows from continuous dispenser (2) onto surface of deposition substrate (5) before grooved film applicator (3), and grooved film applicator (3) adjusts thickness of layer of catalytic ink (1) on surface of deposition substrate (5) forming homogeneously distributed layer of catalytic ink (1). Device comprises continuous dispenser (2) of catalytic ink (1), grooved film applicator (3), and pressure element (7) to press grooved film applicator (3) against deposition substrate (5). Continuous dispenser (2) is placed above plane of deposition substrate (5) and connected to catalytic ink (1) tank.

IPC Classes  ?

• B05C 5/02 - Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work from an outlet device in contact, or almost in contact, with the work
• B05C 11/02 - Apparatus for spreading or distributing liquids or other fluent materials already applied to a surfaceControl of the thickness of a coating
• B01J 37/02 - Impregnation, coating or precipitation
• H01M 4/88 - Processes of manufacture

Abstract

Diffractive optical element The invention relates to smart diffractive elements, namely diffraction gratings and 2D photonic crystals, which optical response can be modified externally via applied magnetic field. This is achieved by magnetic shape memory effect of the used materials. The magnetic shape memory materials serve directly as building blocks in which the diffraction element is fabricated, or as substrates. This innovative approach allows the fabrication of wirelessly programable smart optical elements, which can function in temperature unstable environment, for applications in novel optical systems for computer logic, display technology, sensors of magnetic field, etc.

IPC Classes  ?

• G02B 5/18 - Diffracting gratings
• G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection
• G02F 1/295 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection in an optical waveguide structure
• H10N 35/85 - Magnetostrictive active materials
• G02B 27/42 - Diffraction optics

Abstract

A power supply circuit system of a planar Paul trap, where at least two electrode segments (2) and a ground electrode (11) located on the substrate (1), where the electrode segments (2) are conductively connected to each other. Further, waveguides (3) are located on the substrate (1) arranged in the way that at least one symmetrizing element is connected directly or through an input branch (32) to the input waveguide (31), each symmetrizing element is further connected to at least two resonance branches and each resonance branch is connected directly or through at least one connecting branch (36) to at least one electrode segment (2), and the ground electrode (11) is grounded. The electrode segments (2) and the ground electrode (11) are preferably located on one side of the substrate (1) and the waveguides (3) are located on the opposite side of the substrate (1).

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

The present disclosure provides in one embodiment compounds of formula (I) that are DNA topoisomerase inhibitors useful in treating and/or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy, for example, with anthracycline drugs such as doxorubicin.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• A61K 31/33 - Heterocyclic compounds

Abstract

The present invention relates to 4-amino-2,6-bis(phenylmethylen)cyclohexanones of general formula I wherein R1, R2, R3and R4are independently selected from the group comprising a hydrogen atom, a hydroxy group, a C1-C3 alkoxy group, a trifluoromethoxy group, and a difluoromethoxy group; and R5and R6are independently selected from the group consisting of a C1-C3 alkyl and a hydrogen atom, or R5is a hydrogen atom and R6is an acyl or thioacyl group of general formula II or a sulfonic group of general formula III wherein X is O or S; R7is selected from a group consisting of R8and NH-R8, wherein R822n222nn-(C1-C3 alkyl), C6-C12 aryl, five- to nine-membered heteroaryl, (C6-C12)aryl-(C1-C3)alkyl-, five- to seven-membered heteroaryl-(C1-C3)alkyl-, five- to seven- membered heteroaryl-O-(C1-C3)alkyl-, (C1-C3 alkyl)O-C(O)-(C1-C3)alkyl-, wherein n is 1, 2, 3, 4 or 5, wherein substituent R8222C(=O)-(C1-C3 alkoxy), NHR9, wherein R9is selected from C1–C3 alkyl and NR1022, wherein R10are independently selected from C1-C3 alkyl or both R10together are formed by C2-C5 alkylene, with the proviso that at least one of the substituents R1and R2is not a hydrogen atom, and at least one of the substituents R3and R4 is not a hydrogen atom; and their pharmaceutically acceptable salts, addition salts and solvates. Said compounds are suitable for the treatment of proteinopathies, viral diseases, and diseases directly related to elevated levels of ferroptosis, such as stroke, rhabdomyolysis, non-alcoholic steatohepatitis, acute pancreatitis, and psoriasis.

IPC Classes  ?

• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 31/12 - Antivirals
• C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
• C07C 233/32 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
• C07C 233/61 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
• C07C 235/14 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
• C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07C 275/34 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• C07C 307/08 - Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07C 311/07 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 311/14 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
• C07C 311/29 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Abstract

The present invention relates to the use of bis(phenylmethylene)cycloalkanones and heterocyclic analogues thereof in human and veterinary medicine, for the treatment of diseases caused by the presence or elevated levels of metastable proteins in the cell, imbalances in protein homeostasis and proteotoxic stress, in general proteinopathy, in particular their use in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Kennedy's disease (KD), Huntington's disease (HD), Creutzfeldt-Jakob disease (CJD), spinocerebellar ataxia (SCA), dentatorubral- pallidoluysian atrophy, transthyretin familial amyloid polyneuropathy, systemic amyloidosis, organ- confined amyloidosis, cystic fibrosis, and diabetes. Furthermore, the invention provides novel bis(phenylmethylene)cycloalkanones.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention provides a cell line derived from undifferentiated pleomorphic sarcoma that expresses PD-L1 and collagen and is deposited in the European Collection of Authenticated Cell Cultures under accession number 22113001. This cell line is particularly suitable for immunotherapeutic research, immune cell production and xenotransplantation and/or xenografting in animals.

IPC Classes  ?

• C12N 5/09 - Tumour cells

Abstract

Title: Optical Oxygen Sensor The present invention relates to an optical oxygen sensor, comprising a poly(ɛ-caprolacton) nanofiber 5 membrane doped with platinum (II) complex of octaethylporphyrin, wherein said complex is incorporated within said membrane in an amount in the range of from 0.1 to 4 wt. %. The invention further relates to the use thereof.

IPC Classes  ?

• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
• G01N 21/64 - FluorescencePhosphorescence

Abstract

NaegleriaNaegleria fowleriN. fowleriN. fowleri. Further, activity of compounds carrying a formyl group as direct metabolites of aminomethyl-derivatives as well as activity of prodrugs with a protecting group attached to the amino group that is cleavable under physiological conditions was also shown.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 33/04 - Amoebicides
• A61K 31/69 - Boron compounds

Abstract

332332222, NH(alkyl), NHCO(alkyl), where the alkyl has 1 to 6 carbon atoms, or R1-R2 or R2-R3 or R3-R4 or R5-R6 or R6-R7 or R7-R8 is -CH=CH-CH=CH-, i.e., a fused benzene ring, X and Z are independently H, alkyl of 1 to 6 carbon atoms, benzyl or phenyl. The compounds combine a structural motif suitable for PLpro targeting, have strong affinity and selectivity for RNA over DNA, and at the same time effectively chelate ferric and ferrous ions. Thus, these compounds have the desired properties for potential use as inhibitors of the production of SARS-CoV-2 viral particles and can thus be used for the preparation drugs for the treatment of coronavirus diseases, especially COVID-19.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07D 487/04 - Ortho-condensed systems

Abstract

2232232222222223222232222223232222, where j is in the range of 1 to 12 and R' has the above meaning; where B is phenyl, pyridyl, pyrazinyl, quinolyl, quinoxalyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl, which may be further substituted by one or more of the same or different substituents R, where R has the above meaning, where in the case of doubly charged salts the group B is formed by pyridyl or quinolyl quaternized on its nitrogen atom by A, where A is as defined above, where Y is acetate, acetylacetate, adipate, ascorbate, benzoate, besylate, borate, bromide, butanoate, citrate, deoxycholate, dihydrogen phosphate, phenylacetate, fluoride, phosphate, fumarate, gallate, glutarate, hexafluorophosphate, hippurate, hydrogen sulfate, chloride, perchlorate, cholate, isocyanate, isonicotinate, iodide, caprylate, cyanate, lactate, laurate, lithocholate, malate, maleate, malonate, mandelate, mesylate, monohydrogen phosphate, formate, myristate, napsylate, nicotinate, nitrate, nonafluorobutylsulfonate, oleate, oxalate, oxopropanoate, palmitate, picrate, pimelate, propionate, rhodanide, salicylate, sebacate, cinnamate, stearate, suberate, succinate, sulfate, tetrafluoroborate, tosylate, triflate, trifluoroacetate, trichloroacetate, carbonate, valerate, tartrate, and salts of natural amino acids, for the use as an inhibitor of dihydroorotate dehydrogenase.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention provides a process for the separation of propene from propane through the use of zeolite having PCR structure. The separation process employing adsorbent of the present invention can be used in variety of petrochemical and petroleum refinery processes to purify and separate propene from the mixture of propene and propane.

IPC Classes  ?

• C07C 7/13 - Purification, separation or stabilisation of hydrocarbonsUse of additives by adsorption, i.e. purification or separation of hydrocarbons with the aid of solids, e.g. with ion-exchangers by molecular-sieve technique
• C07C 9/08 - Propane
• C07C 11/06 - Propene
• B01J 23/14 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of germanium, tin or lead
• C01B 37/00 - Compounds having molecular sieve properties but not having base-exchange properties

Abstract

LPAR1DOCK8FUT10PIGGPSD3 CHRNA6DDX4TMEM161B,VPS13AVPS13A genes as Z-specific genes in neognaths.

IPC Classes  ?

• C12Q 1/6879 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination

Abstract

The subject of the invention is azulene hydrazide-hydrazones bearing 2-hydroxyaryl group of general formula I. These compounds show selective cytostatic effect and therefore they can be used for the preparation of medicaments for the treatment of oncological diseases.

IPC Classes  ?

• C07C 251/86 - Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The subject of the invention is pyrrolo[3,2-b]pyrroles with benzohydrazide substitution of general formula I. These compounds show cytostatic effect and inhibitory activity towards TET1 protein. Thus, they can be used for the preparation of a medicament for the treatment of oncological and neurodegenerative disorders and diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61P 35/00 - Antineoplastic agents
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Heme arginate, commonly used to treat acute porphyrias, has been found to inhibit the replication of beta coronaviruses, especially SARS-CoV-2, while protecting infected cells from damage. In addition, heme arginate acts as an immunomodulator. Heme arginate is usable for the treatment of patients infected with SARS-CoV-2 and related beta coronaviruses.

IPC Classes  ?

• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/14 - Antivirals for RNA viruses

Abstract

mm has a value of at least 1, and R is -H or (C1–C10)alkyl, or copolymers thereof.

IPC Classes  ?

• A61L 15/26 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
• A61L 15/46 - Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention provides a module for an on-line permeation test monitoring system, comprising an assembly of two plastic containers, namely a larger main container for culture medium, into which a smaller container forming a cell cultivation insert, filled on at least one side of its inner surface by a continuous cell monolayer, is inserted. The smaller container forms a donor compartment and the interspace between the inserted smaller container and the larger container defines an acceptor compartment. A marker and/or tested substance are added into the donor compartment or the acceptor compartment. The main container further comprises a lid for closing the main container, the lid is provided with at least one inlet and outlet channel for the donor compartment and at least one inlet and outlet channel for the acceptor compartment. Preferably, the plastic module is the 3D-printed module.

IPC Classes  ?

• G01N 33/15 - Medicinal preparations
• G01N 13/00 - Investigating surface or boundary effects, e.g. wetting powerInvestigating diffusion effectsAnalysing materials by determining surface, boundary, or diffusion effects

Abstract

Cardioprotective compounds based on analogues of the compound ICRF-193 of general formula I wherein R1= H, 2-R2-2-aminoacetoxymethyl wherein R2166 alkyl or a branched alkyl of benzyl. These compounds can be produced by simple syntheses and are characterized with low toxicity and high effectiveness of protection of the heart against chronic cumulative cardiotoxicity caused by anthracycline anticancer therapy. The invention provides also a pharmaceutical preparation comprising the compound of general formula (I) as an active ingredient as well as use of this compound for the manufacture of a medicament for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to the preparation, structure and properties of water-soluble polymer therapeutics based on cytarabine derivatives, intended primarily for the treatment of leukaemias and non-Hodgkin's lymphomas in human medicine. Cytarabine is attached to the polymer backbone via amide bond to an amino acid or oligopeptidic sequence situated within the polymer side chain. The structure of cytarabine acylamides enables the stability of the whole polymeric system during blood circulation, and thus its sufficient accumulation in the neoplastic tissue, wherein the drug is allowed to be released hydrolytically. The present invention further relates to the polymeric cytostatics, which is stable in blood stream, to the pharmaceutical composition and use thereof in medicine.

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Abstract

2222; R is independently selected from the group consisting of (Cl-C6)alkyl, which may be linear or branched; (C5-C6)cykloalkyl; R1is H, (C1-C6)alkyl, which may be linear or branched; or (C5-C6)cykloalkyl; R2to R6are independently selected from the group consisting of -H, (Cl-C6)alkyl, (Cl- C6)alkoxyl, -N(R7)2, wherein R7 is independently (Cl-C6)alkyl; wherein the compound of general formula (I) bears at least one positive charge. The invention further relates to the methods of synthesis thereof and their use for modification of negatively charged solid surfaces.

IPC Classes  ?

• C07D 233/60 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
• C07D 213/20 - Quaternary compounds thereof
• C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
• C08L 5/16 - CyclodextrinDerivatives thereof
• B01J 20/32 - Impregnating or coating

Abstract

Method of measurement of knee strength characteristics is carried out in a manner that measured person in upright position leans against dynamometers with bearing surfaces (3) and movable arm (2) and starts transition to the sitting position, thus acting on the movable arm (2), which through connected sensor (21) of angular position monitors speed of change in angular position of the movable arm (2) and acts on dynamometers with bearing surfaces (3), which measure strength generated by measured person for each lower extremity individually, whereas sensor (21) of angular position and dynamometers transmit collected data to control unit, which evaluates speed of change in angular position of movable arm (2) and visualization equipment (4) shows to measured person actual and requested speed of change in angular position of movable arm (2) in a manner that measured person adjusts speed of transition from upright to sitting position to requested speed.

IPC Classes  ?

• A61B 5/22 - ErgometryMeasuring muscular strength or the force of a muscular blow
• A63B 21/002 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices isometric or isokinetic, i.e. substantial force variation without substantial muscle motion
• A63B 23/04 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously for lower limbs

Abstract

N2q2rpqrr are independently selected from 1, 2 and 3; Y is selected from the group consisting of a bond, - C(=0)-NH-, -NH-C(=0)-, -NH-C(=S)-NH-; the molecular weight Mn of the linear semitelechelic copolymer is in the range of from 10,000 to 100,000 g/mol; and the fluorophore has a molecular weight in the range of from 350 to 1,500 g/mol, an excitation wavelength in the range of from 300 to 850 nm and an emission wavelength in the range of from 350 to 1,200 nm. The present invention further relates to a fluorescent probe, a conjugation kit, a method of their preparation and to the use thereof.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C08F 220/56 - AcrylamideMethacrylamide
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 220/60 - Amides containing nitrogen in addition to the carbonamido nitrogen
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide

Abstract

The interface for the system of sampling, preparation, and analysis of a sample, especially by capillary electrophoresis, consists of a cross connector (10), sampling capillary (12), separation capillary (15), capillary (11) supplying BGE, and ground capillary (14), wherein walls of the cross connector (10) channels fit tightly onto at least three capillaries of an outer diameter of 300 μm to 800 μm, and the internal volume (16) of the cross connector (10) is less than 0.5 µL, preferably the internal volume (16) is 0.1 µL, and the capillary, onto which the cross connector (10) channel does not fit, is sealed in the cross connector (10) channel with an adhesive (13).

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

233), yttrium aluminium garnet, aluminium nitrate spinel, or magnesium aluminium spinel, quartz.

IPC Classes  ?

• C30B 13/14 - Crucibles or vessels
• C30B 13/24 - Heating of the molten zone by irradiation or electric discharge using electromagnetic waves
• C30B 13/32 - Mechanisms for moving either the charge or the heater
• C30B 29/52 - Alloys

Abstract

The present invention provides a structurally novel class of heterocyclic compounds of general formula I wherein L1 is heteroaryl and L2 is heteroaryl or aryl. The novel compounds are useful in a method of prevention or treatment of a condition which is mediated by the action, or by loss of action, of Constitutive androstane receptor (CAR) receptor or its endogenous ligands. The present invention thus provides the novel compounds for medicinal use, as well as pharmaceutical composition containing said compounds. (I)

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

22 and inert gas is formed and igniting the plasma which leads to simultaneous plasma etching of the membrane surface and deposition of cerium oxide onto the surface of etched membrane resulting in formation of fibers (2). The membrane (1) is made of polymer and on at least one of its sides features porous surface made of fibers (2), the cross-sectional dimensions of which are lower than their length and which are integral and inseparable part of membrane (1) body.

IPC Classes  ?

• H01M 4/88 - Processes of manufacture
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1086 - After-treatment of the membrane other than by polymerisation
• H01M 8/1018 - Polymeric electrolyte materials

Abstract

The invention relates to a pharmacy preparation for malignant melanoma treatment containing combination of active ingredients, being GANT61, Obatoclax with the advantage of its mesylate salt, and agent selected from the group comprising (+)-JQ1, SGI-7079, GSK343, GSK126, HA15, wherein concentration of active ingredients in the specific triple-combination necessary to eradicate tumor cells is as follows: a) GANT61 from 10 to 20 μmol/l; b) Obatoclax from 150 to 300 nmol/l; cl) (+)-JQ1 from 125 to 500 nmol/l; c2) SGI-7079 from 125 to 500 nmol/l; c3) GSK343 from 0.25 to 1,0 μmol/l; c4) GSK126 from 25 to 100 nmol/l; and c5) HA15 from 2.5 to 10 μmol/l. All triple-combinations are highly effective in the experiments carried-out on cell cultures of human melanoma cells, when all tumor cells were eradicated not later than 7th day after application.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 35/00 - Antineoplastic agents

Abstract

The device for lower extremity muscle force measurement in isokinetic movement conditions consists of a supporting surface (3) for knees, angular position sensor (4) equipped with an arm (5), stand with dynamometers (2) and a control unit equipped with an imaging device and containing firmware to measure, record and evaluate data from the angular position sensor (4) and dynamometers (2) connected to it. Procedure for the measurement carried out on the device is defined by the forward angular motion of the measured person kneeling on the supporting surface (3), thus producing pressure on the arm (5) that is pushed in the direction and speed of the measured person's motion, wherein the control unit (6) evaluates the change in angular position of the arm (5) and indicates the current and required speed of change in angular position on the imaging device to maintain the isokinetic movement.

IPC Classes  ?

• A61B 5/22 - ErgometryMeasuring muscular strength or the force of a muscular blow

Abstract

The invention provides methods for imaging biological tissue. The disclosed polymethenium salts show activity as two photon imaging agents, having a greater imaging depth and photostability than known agents, whilst having lower toxicity. The methods show great selectivity for mitochondria. The methods have utility in both in vitro and in vivo imaging, for example, imaging of tumours.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 49/00 - Preparations for testing in vivo
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines

Abstract

The invention provides a polymeric thermoplastic biodegradable composition incorporating an antibiotic, in particular for production of inserts for the treatment and prevention of local infections, consisting of (a) at least one plastified polysaccharide component, which is selected from starch, a mixture of starch and maltodextrin, esterified starch, and a mixture of esterified starch and esterified maltodextrin, wherein maltodextrin is a mixture of oligosaccharides having the dextrose equivalent of at most 25, whereas the polysaccharide component further contains an antibiotic, and (b) a polyester component which is poly-ε-caprolactone and/or poly[(ε-caprolactam)-co-(ε-caprolactone)] containing at least 10 % of crystalline phase and having the crystalline phase melting temperature lower than 65 °C, in the weight ratio (a):(b) in the range of 4:1 to 1:9. Additionally, method of preparation of such composition is described.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The invention concerns a measuring instrument, a combined seismic sensor system that can measure 9 components of seismic motion, i.e. 3 orthogonal translational components, 3 components of rotation around orthogonal axes and 3 strain components at the measuring point. The system according to the invention comprises a solid undeformable frame, horizontal and vertical seismic sensors and optical dilatometers. The invention also includes a method of seismic measurement using the instrument. The instrument is suitable for measuring wavefields generated both by artificial sources (mine blasts, generators of rotational motions) and by natural sources (e.g. local earthquakes, rockbursts etc.)

IPC Classes  ?

• G01V 1/18 - Receiving elements, e.g. seismometer, geophone
• G01V 1/16 - Receiving elements for seismic signalsArrangements or adaptations of receiving elements
• G01V 13/00 - Manufacturing, calibrating, cleaning, or repairing instruments or devices covered by groups
• G01V 1/02 - Generating seismic energy

Abstract

Cyclam based compounds, their conjugates, co-ordination compounds, pharmaceutical composition containing thereof, method of preparation and use thereof The present invention relates to cyclam based compounds of the general formula (I), conjugates of such compounds with conjugation groups, their coordination compounds, targeting conjugates, method of preparation of cyclam based compounds, intermediate products for the preparation of cyclam based compounds, a pharmaceutical preparation containing them, and the use thereof.

IPC Classes  ?

• C07F 9/30 - Phosphinic acids [R2=P(:O)OH]Thiophosphinic acids
• C07F 9/38 - Phosphonic acids [R—P(:O)(OH)2]Thiophosphonic acids
• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

An intelligent sensor network for automatic collection and administration of data characterizing the physiological functions and physical activity of the user, comprising a set of sensors (1) and at least one user's peripheral (2). The sensors (1) are interconnected, via a user's peripheral (2), with a central server (3). The central server (3) is equipped with a block (4) for sending feedback. The central server (3) is interconnected with a social network server (6). The central server (3) is equipped with a block (7) for automatic monitoring of the user's electronic communication. The central server (3) is further equipped with a block (5) for automatic classification of the user's physical activity based on the output from the block (7) for automatic monitoring of the user's electronic communication.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

Substituted 2-(2-phenylhydrazinyl)pyrazine of general formula I, wherein each R1, R2 is independently H or CN; R3 is CH3 or CONH2; each R4, R5, R6, R7, R8 is independently H, CI, or NO2. The invention further provides a method for preparing such substances, in which the appropriate substituted chloropyrazine is treated with a substituted phenylhydrazine under conditions of microwave synthesis. The compounds of general formula I are characterized by their low toxicity and high activity against mycobacteria. They can also be used in pharmaceutical preparations as antitubercular drugs.

IPC Classes  ?

• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• A61K 31/4965 - Non-condensed pyrazines
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

Antitubercular active compounds based on oxyphosphorus acids derivatives of substituted salicylanilides of general formula I, wherein each R1, R2 is independently H, halogen, or NO2; each R3, R4 is independently H, halogen, NO2, or CF3; R5 is H, halogen, or NO2; R6 is C2- C16alkyl, C6-C18aryl, C6-C18aryloxy, or C6-C18arylC2-C16alkyloxy; R7 is C6-C18aryl, C6- C18aryloxy, C6-C18aryl C2-C16alkyloxy, or R7 is missing; R8 is H or single bond to phosphorus atom. These compounds can be obtained by simple synthetic procedures and they show high in vitro antimycobacterial activity including multidrug-resistant strains. The invention provides also the use of these compounds as antitubercular and/or antimycobacterial drugs as well as a pharmaceutical preparation containing as an active substance compound of general formula I.

IPC Classes  ?

• C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• C07F 9/145 - Esters of phosphorous acids with hydroxyaryl compounds
• C07F 9/32 - Esters thereof
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

A shockwave applicator (15), especially for clinical use in oncology, that comprises a first electrode (1) having the shape of a hollow cylinder, which is covered with a porous insulating layer (3) on its outer surface. The first electrode (1) is surrounded by a second electrode (2) of a reflector shape. Between the first electrode (1) and the second electrode (2) a high-voltage impulse source (6) and an isolator (4) are arranged. The space between the electrodes (1, 2) is filled with liquid (11) with defined conductivity. In the hollow space inside the first electrode (1) an ultrasonic probe (5) is mounted in a sliding way. The ultrasonic probe (5) has a defined end position inside the first electrode (1) defined by a stop (7) and the cavity inside the first electrode (1) is protected from liquid (11) penetration with a membrane (8) of an acoustically transparent material. A shockwave application system, especially for clinical use in oncology, comprising a bed (12) for placing the patient, where the patient surface of the bed is fitted with an opening (13) under which the shockwave applicator (15) according to the invention is attached in a liquid-proof and adjustable manner.

IPC Classes  ?

• A61B 17/225 - Surgical instruments, devices or methods for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
• G10K 15/04 - Sound-producing devices
• G10K 11/28 - Sound-focusing or directing, e.g. scanning using reflection, e.g. parabolic reflectors

Abstract

A nitro group-substituted phenyltetrazole of general formula (I) wherein R is selected from the group consisting of: H, C1-C11 alkyl, phenyl- or phenyl- substituted in positions 2, 3, 4 or 5 by one or more electron-acceptor groups and/or by one or more electron-donor groups. These compounds can be prepared by easy synthesis and have significant activity against mycobacteria including their multidrug resistant strains. The invention provides also a pharmaceutical preparation having nitro group-substituted phenyltetrazole of formula (I) as the active ingredient, as well as the use of this nitro group-substituted phenyltetrazole as antituberculosis drug.

IPC Classes  ?

• C07D 257/04 - Five-membered rings
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

The invention relates to an electrode, which allows, after application on a skin, electrically stimulating appropriate nerve plexus localized in a tissue under the skin. Preferably, the electrode is intended for stimulating the nerves in lower limbs in treatment of dysfunction of lower urinary tract (urinary incontinence). The invention further relates to a detector of reflective movements for use in electric neurostimulation treatment. The detector is intended for automatic adjusting of the neurostimulation pulses frequency to an optimum value, which matches the resonance of stimulation electric impulses with induced motor reflexes of corresponding muscle groups. By the use of the detector it is possible to considerably raise the efficiency of neurostimulation, shorten and streamline duration of such a treatment. Furthermore, the invention relates to an electrostimulation device comprising the electrode or the detector according to the invention, preferably both the electrode and the detector.

IPC Classes  ?

• A61N 1/04 - Electrodes
• A61N 2/00 - Magnetotherapy
• A61N 2/06 - Magnetotherapy using magnetic fields produced by permanent magnets
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• G01P 15/09 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by piezoelectric pick-up
• G01C 9/10 - Measuring inclination, e.g. by clinometers, by levels by using rolling bodies
• G01H 11/08 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by detecting changes in electric or magnetic properties by electric means using piezoelectric devices

Abstract

The invention relates to a carrier for oromucosal, especially sublingual administration of physiologically active substances, especially of medicinal drugs, which consists of at least one elastic layer (1) of polymer nanofibres workable according to the shape of the selected wall of mouth cavity to which it should be applied and in this elastic layer (1) of polymer nanofibres a drug and/or other physiologically active substance are deposited in a releasable manner.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The invention relates to the use of at least one recombinant mammalian galectin selected from the group comprising galectin-1, galectin-4 and galectin-7 as inductors of fibroblast-to-myofibroblast transition and/or production of extracellular matrix nanofibers. The invention further relates to a method of preparation of myofibroblasts and/or extracellular matrix nanofibers wherein the fibroblasts are in vitro cultivated in the presence of at least one recombinant mammalian galectin selected from the group comprising galectin-1, galectin-4 and galectin-7. Combination of a galectin and TGF-ß1 exerts a synergic effect. Further, the invention relates to extracellular matrix nanofibers in the form of three-dimensional scaffolds obtainable by the method of this invention. ˙

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

An ultrasonic probe for liquids temperature measurement with the following features. The liquid is contained by a container made of a plastic-elastic material (1). On the outher surface of the container two piezoelectric transducers abut, one of which is the mechanical waves transmitter (P1) and the other the mechanical waves recevier (P2). Both the transmitter and the recevier keep a stable position relative to the container wall (1) as well as a stable position opposite each other.

IPC Classes  ?

• G01K 1/14 - SupportsFastening devicesArrangements for mounting thermometers in particular locations
• G01K 11/24 - Measuring temperature based on physical or chemical changes not covered by group , , , or using measurement of acoustic effects of the velocity of propagation of sound
• G01K 13/02 - Thermometers specially adapted for specific purposes for measuring temperature of moving fluids or granular materials capable of flow

Abstract

A method for preparing oxidation catalyst comprising cerium oxide and a metal selected from the group consisting of gold, platinum palladium, tin, ruthenium, or nickel by sputtering cerium oxide and a metal from a target to a substrate wherein the cerium oxide and a metal material are sputtered to the substrate concurrently from at least one target under an argon atmosphere t form a layer of cerium oxide including dispersed atoms of the metal Specific Au-CeO2 and Pt-CeO2 catalysts are prepared by using this method.

IPC Classes  ?

• B01J 37/34 - Irradiation by, or application of, electric, magnetic or wave energy, e.g. ultrasonic waves
• H01M 4/90 - Selection of catalytic material

Abstract

The subject-matter of the invention is the method of measuring mechanical properties of materials, namely biological materials, when at least one parameter characterising the viscoelasticity of the material is detected; the method consists in attaching an inertial member to the measured sample of the viscoelastic material or to the probed put into contact with the sample of the viscoelastic material, the weight of the inertial member being substantially higher than the weight of the sample or probe, while the inertial member or probe are at least partially formed of ferromagnetic material; by means of a contactless sensor, impulse and/or transient characteristics in straining the sample in bending, tension, compression or torsion are measured. Another subject-matter of the invention is an apparatus for carrying out the method according to the invention, i.e. the inertial viscoelastometer. In an advantageous embodiment, the apparatus according to the invention is modified for determining viscoelasticity of materials in straining the sample in bending, tension or compression. Another advantageous embodiment enables to determine the viscoelasticity based on measuring the surface of the sample or to determine the viscoelasticity of a sample in the form of a membrane.

IPC Classes  ?

• G01N 3/00 - Investigating strength properties of solid materials by application of mechanical stress

Abstract

The invention relates to formation comprising at least one nanofibre layer. Said nanofibres have a diameter up to 600 nm produced through electrostatic spinning of polymer solution. The layer of polymer nanofibres comprises particles of photodynamic sensitizer, at the same time the nanofibres are isotropic spread in a transparent and porous layer of surface weight from 0,01 g/m2 to 15 g/m2. Next to this, the invention relates to the production method of nanofibre layer through electrostatic spinning of polymer solution in electric field created by difference of potentials between the spinning electrode and collecting electrode, while the nanofibres produced in this electric field are carried to the collecting electrode and they deposit on a surface designated to it. The polymer solution for spinning contains particles of photodynamic sensitizer, which are during spinning seized together with polymer into the nanofibres being produced, in which these particles are anchored inside or on the surface

IPC Classes  ?

• D01D 5/00 - Formation of filaments, threads, or the like
• D01F 1/10 - Other agents for modifying properties
• D01F 6/18 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of unsaturated nitriles, e.g. polyacrylonitrile, polyvinylidene cyanide
• D01F 6/70 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolycondensation products from polyurethanes
• D06M 13/352 - Heterocyclic compounds having five-membered heterocyclic rings
• D06M 13/503 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compoundsSuch treatment combined with mechanical treatment with organometallic compoundsTreating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compoundsSuch treatment combined with mechanical treatment with organic compounds containing boron, silicon, selenium or tellurium atoms without bond between a carbon atom and a metal or a boron, silicon, selenium or tellurium atom
• D06M 16/00 - Biochemical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. enzymatic

Abstract

The invention relates to a method of cultivation of mesenchymal stem cells, wherein after aseptic separation of mononuclear cells from the marrow blood, said cells are seeded in low density into sterile plastic cultivation vessels and cultivated for approximately one to three weeks in CellGroTM Hematopoietic Stem Cell Medium, certified for the clinical use, with an addition of 10% human serum and supplements, wherein the supplements are added at least once in the course of the cultivation, without removal of hematopoietic cells and without medium exchange during the cultivation procedure, without any interference with the closed cultivation system, under the standard conditions for the cultivation of tissue cultures. For the cultivation of the mesenchymal stem cells in the closed cultivation system for the clinical use in the field of orthopaedic surgery, a simple bioreactor is proposed. The bioreactor consists of a cassette system containing cultivation vessels with filters for securing the sterile exchange of gas and with aseptic inlets for seeding and harvesting the cells and adding the supplements, and a carrier.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells